Drug Trial Radar · NCT02160782
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
Last checked: Nov 20, 2026Latest source record: Jul 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Oct 28, 2014
Primary completion
May 28, 2020
Study completion May 28, 2020
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period in children with Alagille Syndrome (ALGS) designed to evaluate the safety and efficacy of LUM001 (Also known as maralixibat or MRX).
Conditions
- Alagille Syndrome
Interventions
LUM001 (Maralixibat)Drug
LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
PlaceboDrug
Placebo will be administered orally once daily during randomized withdrawal period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18Time frame: Week 18 to Week 22
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
Children's Hospital Westmead
Westmead, New South Wales, Australia
The Royal Children's Hospital Melbourne
Parkville, Victoria, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hopital Femme Mere Enfant De Lyon
Bron, France
Hopital Necker-Enfants Malades
Paris, France
Hopital Kremlin Bicetre
Paris, France
The Children's Memorial Health Institute
Warsaw, Poland
Hospital Universitario La Paz- Hospital Materno Infantil
Madrid, Spain
Paediatric Liver Center, Kings College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.